We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of RX-10045 in the Treatment of Dry Eye Disease

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01675570
First Posted: August 30, 2012
Last Update Posted: February 11, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
C.T. Development America, Inc.
  Purpose
The primary purpose of this study is to assess the efficacy, tolerability and safety of RX-10045 Ophthalmic Solution in patients with Dry Eye Disease.

Condition Intervention Phase
Dry Eye Syndrome Drug: RX-10045 Drug: Vehicle for RX-10045 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase II, Multi-Center, Randomized, Placebo-Controlled, Double-Masked Study of RX-10045 (0.09%) in the Treatment of Dry Eye Disease

Resource links provided by NLM:


Further study details as provided by C.T. Development America, Inc.:

Primary Outcome Measures:
  • Corneal staining [ Time Frame: Baseline to day 28 ]
  • Worst symptom score [ Time Frame: Baseline to day 28 ]

Secondary Outcome Measures:
  • Ocular discomfort symptom score [ Time Frame: Baseline to day 28 ]
  • Tear film break-up time [ Time Frame: Baseline to day 28 ]
  • Visual-related function subscale of Ocular Surface Disease Index score [ Time Frame: Baseline to day 28 ]

Enrollment: 150
Study Start Date: August 2012
Study Completion Date: November 2012
Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: RX-10045 active arm
RX-10045 Opththalmic Solution, 0.09%
Drug: RX-10045
One drop of RX-10045 ophthalmic solution will be instilled in each eye, twice a day, approximately 12 hours apart for 28 days.
Placebo Comparator: Vehicle for RX-10045 arm
Vehicle of RX-10045 Ophthalmic Solution
Drug: Vehicle for RX-10045
One drop of RX-10045 placebo solution will be instilled in each eye, twice a day, approximately 12 hours apart for 28 days.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Have a patient reported history of dry eye in both eyes
  2. Presence of dry eye symptoms
  3. Presence of dry eye signs, destabilized tear film break-up time and corneal staining

Exclusion Criteria:

  1. Known contraindications or sensitivities to study medication or its components
  2. Any ocular condition that, in the opinion of the investigator, could affect the subject's safety or trial parameters
  3. Use of disallowed medication during the period indicated prior to the enrollment or during the study
  4. Be a female who is currently pregnant, planning a pregnancy, lactating, or not using a medically acceptable form of birth control
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01675570


Locations
United States, Massachusetts
Andover Eye Associates
Andover, Massachusetts, United States, 01810
Sponsors and Collaborators
C.T. Development America, Inc.
Investigators
Principal Investigator: Gail Torkildsen, MD Andover Eye Associates
  More Information

Responsible Party: C.T. Development America, Inc.
ClinicalTrials.gov Identifier: NCT01675570     History of Changes
Other Study ID Numbers: CTD1201
First Submitted: August 28, 2012
First Posted: August 30, 2012
Last Update Posted: February 11, 2013
Last Verified: February 2013

Keywords provided by C.T. Development America, Inc.:
RX-10045
Dry Eye Disease

Additional relevant MeSH terms:
Keratoconjunctivitis Sicca
Dry Eye Syndromes
Eye Diseases
Keratoconjunctivitis
Conjunctivitis
Conjunctival Diseases
Keratitis
Corneal Diseases
Lacrimal Apparatus Diseases
Pharmaceutical Solutions
Ophthalmic Solutions